HIV-1 Tat protein: A target for the development of anti-AIDS therapies

Drugs of the Future

Volumn 27, Issue 5, 2002, Pages 481-493

  Rusnati, Marco ^a   Presta, Marco ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; 5,6 DICHLOROBENZIMIDAZOLE RIBOSIDE; [7 CHLORO 5 (1H PYRROL 2 YL) 3H BENZO[E][1,4]DIAZEPIN 2 YL]METHYLAMINE; ARGINYLGLYCYLASPARTIC ACID; ARISTEROMYCIN; BROMAZEPAM; CURCUMIN; DEXTRIN 2 SULFATE; DIAZEPAM; DISTAMYCIN A DERIVATIVE; GLYCYCLAMIDE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; K 37; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (6 AMINOHEXYL)GLYCYL N (3 GUANIDINOPROPYL)GLYCYL N (3 GUANIDINOPROPYL)GLYCYL N BENZYLGLYCYL N (3 GUANIDINOPROPYL)GLYCYL DEXTRO LYSYL DEXTRO LYSYL DEXTRO ARGINYL DEXTRO PROLINAMIDE; NEAMINE; NEOMYCIN; PENTOSAN POLYSULFATE; PENTOXIFYLLINE; PNU 151779; PNU 157666; PROTEIN KINASE C INHIBITOR; QUINOLONE DERIVATIVE; RECEPTOR BLOCKING AGENT; SCH 221153; STAUROSPORINE; TAT RECEPTOR ANTAGONIST; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; GENE THERAPY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; REVIEW; VIRUS REPLICATION;

EID: 0036323246     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2002.027.05.680587     Document Type: Review

References (155)

1. Long-term cultures of HTLV-III-infected T cells: A model of cytopathology of T-cell depletion in AIDS
2. Interferon and interferon inhibitor levels in patients infected with varicella-zoster virus, acquired immunodeficiency syndrome, acquired immunodeficiency syndrome-related complex, or Kaposi's sarcoma, and in normal individuals
3. Interferon α and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS
4. Multiple functions of human immunodeficiency virus type 1 Tat protein in the pathogenesis of AIDS
5. Multifaceted activities of the HIV-1 transactivator of transcription, Tat
6. Tat as a transcriptional activator and a potential therapeutic target for HIV-1
7. From the outside in: Extracellular activities of HIV Tat
8. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120
9. + T cells
10. Inhibition of CXCR4-dependent HIV-1 infection by extracellular HIV-1 Tat
11. Uptake of HIV-1 tat protein mediated by low-density lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the receptor ligands
12. Internalization of HIV-1 Tat requires cell surface heparan sulfate proteoglycan
13. Neuropathogenesis of AIDS
14. Reciprocal regulatory interaction between human herpesvirus 8 and human immunodeficiency virus type 1
15. Does HIV tat protein also regulate genes of other viruses present in HIV infection?
16. Interactions between human immunodeficiency virus type 1 and human cytomegalovirus in human term syncytiotrophoblast cells coinfected with both viruses
17. Gene therapy and immune restoration for HIV disease
18. Genetic therapies for HIV infections: Promise for the future
19. HIV-1 Tat protein as a potential AIDS vaccine
20. The basic domain in HIV-1 Tat protein as a target for polysulfated heparin-mimicking extracellular Tat antagonists
21. Conformational heterogeneity in two regions of TAT results in structural variations of this protein as a function of HIV-1 isolates
22. Human trials of HIV-1 vaccines
23. AIDS epidemic at the beginning of the third millennium: Time for a new AIDS vaccine strategy
24. Differences in time of virus appearance in the blood and virus-specific immune responses in intravenous and intrarectal primary SIVmac251 infection of rhesus macaques: A pilot study
25. Cytotoxic T lymphocyte activity in children infected with HIV
26. The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals
27. Antibody against human immunodeficiency virus type 1 (HIV-1) Tat protein may have influenced the progression of AIDS in HIV-1-infected hemophiliac patients
28. Relationship between the presence of anti-Tat antibody, DNA and RNA viral load
29. Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS
30. Tat protein induces self-perpetuating permissivity for productive HIV-1 infection
31. Control of SHIV- 89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine
32. Tat as one key to HIV-induced immune pathogenesis and Tat toxoid as an important component of a vaccine
33. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P)
34. Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge
35. A prophylactic and therapeutic AIDS vaccine containing as a component the innocuous Tat toxoid
36. Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients
37. Vaccination with Tat toxoid attenuates disease in simian/HIV-challenged macaques
38. Antibody spectrum against the viral transactivator protein in patients with human immunodeficiency virus type 1 infection and Kaposi's sarcoma
39. Characterization of HIV type 1 tat sequences associated with perinatal transmission
40. Immunization with a novel HIV-1-Tat multiple-peptide conjugate induces effective immune response in mice
41. Identification of a peptide capable of inducing an HIV-1 Tat-specific CTL response
42. Characterization of HIV-1 Tat proteins mutated in the transactivation domain for prophylactic and therapeutic application
43. Minimization of chronic plasma viremia in rhesus macaques immunized with synthetic HIV-1 Tat peptides and infected with a chimeric simian/human immunodeficiency virus (SHIV33)
44. DNA immunization with HIV-1 Tat mutated in the trans activation domain induces humoral and cellular immune responses against wild-type Tat
45. Nucleic acid vaccination with HIV regulatory genes: A combination of HIV-1 genes in separate plasmids induces strong immune responses
46. Enhancement of humoral immunity to SIVenv following simultaneous inoculation of mice by three recombinant adenoviruses encoding SIVenv/poliovirus chimeras, Tat and Rev
47. Vaccination with Rev and Tat against AIDS
48. Interactions of single and combined human immunodeficiency virus type 1 (HIV-1) DNA vaccines
49. Interaction of HIV-1 Tat protein with heparin: Role of the backbone structure, sulfation, and size
50. Multiple interaction of HIV-1 Tat protein with size-defined heparin oligosaccharides
51. Characterization of the effects of two polysulfonated distamycin A derivatives, PNU145156E and PNU153429, on HIV type 1 Tat protein
52. Antiangiogenic, antitumoural and antimetastatic effects of two distamycin A derivatives with anti-HIV-1 Tat activity in a Kaposi's sarcoma-like murine model
53. Interaction of the transactivating protein HIV-1 Tat with sulphated polysaccharides
54. Pentosan polysulfate as inhibitor of extracellular HIV-1 Tat
55. Toward a biotechnological heparin through combined chemical and enzymatic modification of the Escherichia coli K5 polysaccharide
56. Fibroblast growth factor-2 antagonist activity and angiostatic capacity of sulfated Escherichia coli K5 polysaccharide derivatives
57. The angiogenesis induced by HIV-1 Tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells
58. 5 integrin receptor antagonist
59. Curcumin and curcumin derivatives inhibit Tat-mediated transactivation of type 1 human immunodeficiency virus long terminal repeat
60. Inhibition of HIV-1 Tat-mediated transactivation by quinacrine and chloroquine
61. (1/2) by extracellular HIV-1 Tat protein
62. Pro-inflammatory and pro-oxidant properties of the HIV protein Tat in a microglial cell line: Attenuation by 17β-estradiol
63. CT-2576, an inhibitor of phospholipid signaling, suppresses constitutive and induced expression of human immunodeficiency virus
64. Diazepam inhibits HIV-1 Tat-induced migration of human microglia
65. Transdominant mutants of I κ B α block Tat-tumor necrosis factor synergistic activation of human immunodeficiency virus type 1 gene expression and virus multiplication
66. IL-16 represses HIV-1 promoter activity
67. Nitric oxide inhibits HIV Tat-induced NF-κB activation
68. Antitat gene therapy: A candidate for late-stage AIDS patients
69. Anti-HIV genetic treatment of antigen-specific human CD4 lymphocytes for adoptive immunotherapy of opportunistic infections in AIDS
70. Inhibition of HIV-1 replication in chronically infected cell lines and peripheral blood mononuclear cells by retrovirus-mediated antitat gene transfer
71. Efficacy of antitat gene therapy in the presence of high multiplicity infection and inflammatory cytokines
72. Reduction in SIV replication in rhesus macaques infused with autologous lymphocytes engineered with antiviral genes
73. The hydrolysis of RNA: From theoretical calculations to the hammerhead ribozyme-mediated cleavage of RNA
74. Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme
75. Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes
76. Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA
77. + hematopoietic progenitor cells transduced with an anti-HIV ribozyme
78. tRNAVal-heterodimeric maxizymes with high potential as gene inactivating agents: Simultaneous cleavage at two sites in HIV-1 Tat mRNA in cultured cells
79. Preclinical characterization of an anti-tat ribozyme for therapeutic application
80. Novel mono- and di-DNA-enzymes targeted to cleave TAT or TAT-REV RNA inhibit HIV-1 gene expression
81. Inhibition of HIV-1 gene expression by novel macrophage-tropic DNA enzymes targeted to cleave HIV-1 TAT/Rev RNA
82. + hematopoietic progenitor cells with an antitat gene protects T-cell and macrophage progeny from AIDS virus infection
83. + cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes
84. + cells transduced with an intracellular antibody directed against human immunodeficiency virus type 1 Tat
85. Oligonucleotide analogue interference with the HIV-1 Tat protein-TAR RNA interaction
86. Inhibition of HIV-1 Tat-dependent trans activation by steric block chimeric 2′-O-methyl/LNA oligoribonucleotides
87. Block of HIV-1 infection by a combination of antisense tat RNA and TAR decoys: A strategy for control of HIV-1
88. Inhibition of HIV-1 in CEM cells by a potent TAR decoy
89. SV40-derived vectors provide effective transgene expression and inhibition of HIV-1 using constitutive, conditional, and pol III promoters
90. A small circular TAR RNA decoy specifically inhibits Tat-activated HIV-1 transcription
91. Inhibition of human immunodeficiency virus type 1 replication is enhanced by a combination of transdominant Tat and Rev proteins
92. Inhibition of human immunodeficiency virus type 1 and type 2 Tat function by transdominant Tat protein localized to both the nucleus and cytoplasm
93. Inhibition of HIV-1 replication by a Tat transdominant negative mutant in human peripheral blood lymphocytes from healthy donors and HIV-1-infected patients
94. Inhibition of Tat-mediated transactivation and HIV replication with Tat mutant and repressor domain fusion proteins
95. Inhibition of HIV-1 transcription and virus replication using soluble Tat peptide analogs
96. An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication
97. Inhibition of HIV-1 replication by a Tat RNA-binding domain peptide analog
98. Binding of Hoechst 33258 to the TAR RNA of HIV-1. Recognition of a pyrimidine bulge-dependent structure
99. Aromatic polyamidines inhibiting the Tat-induced HIV-1 transcription recognize structured TAR-RNA
100. Tetrahydropyrimidine derivatives inhibit binding of a Tat-like, arginine-containing peptide, to HIV TAR RNA in vitro
101. Human anti-HIV-1 Tat sFv intrabodies for gene therapy of advanced HIV-1-infection and AIDS
102. + mononuclear cells expressing murine and humanized anti-human immunodeficiency virus type 1 Tat single-chain variable fragment intrabodies
103. Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies
104. Development of a functional backbone cyclic mimetic of the HIV-1 Tat arginine-rich motif
105. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication
106. HIV-1 replication is inhibited by a pseudo-substrate peptide that blocks Tat transactivation
107. Different members of the Sp1 multigene family exert opposite transcriptional regulation of the long terminal repeat of HIV-1
108. Inhibition of human immunodeficiency virus type 1 transcription and replication by DNA sequence-selective plant lignans
109. Inhibition of HIV replication in acute and chronic infections in vitro by a Tat antagonist
110. Restoration of cell surface CD4 expression in human immunodeficiency virus type 1-infected cells by treatment with a Tat antagonist
111. Discovery and characterization of an HIV-1 Tat antagonist
112. Inhibition of type 1 human immunodeficiency virus replication by a Tat antagonist to which the virus remains sensitive after prolonged exposure in vitro
113. A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection
114. HIV replication in chronically infected macrophages is not inhibited by the Tat inhibitors Ro-5-3335 and Ro-24-7429
115. 2-Glycineamide-5-chlorophenyl 2-pyrryl ketone, a non-benzodiazepin Tat antagonist, is effective against acute and chronic HIV-1 infections in vitro
116. Inhibition of the RNA-dependent transactivation and replication of human immunodeficiency virus type 1 by a fluoroquinoline derivative K-37
117. Inhibition of human immunodeficiency virus type 1 replication and cytokine production by fluoroquinoline derivatives
118. Inhibition of human immunodeficiency virus type 1 replication in acutely and chronically infected cells by EM2487, a novel substance produced by a Streptomyces species
119. Inhibition of tat-activated, HIV-1 long terminal repeat-mediated gene expression by glucocorticoids
120. D-Penicillamine inhibits transactivation of human immunodeficiency virus type-1 (HIV-1) LTR by transactivator protein
121. Inhibition of Tat-mediated HIV-1-LTR transactivation and virus replication by sulfhydryl compounds with chelating properties
122. Camptothecin inhibits Tat-mediated transactivation of type 1 human immunodeficiency virus
123. Canventol inhibits HIV-1 replication by Tat-induced Tar-independent mechanism
124. Keto/enol epoxy steroids as HIV-1 Tat inhibitors: Structure-activity relationships and pharmacophore localization
125. β interferon inhibits HIV-1 Tat-induced angiogenesis: Synergism with 13-cis retinoic acid
126. 3 integrin
127. The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1α
128. Dextran sulfate and heparin interact with CD4 molecules to inhibit the binding of coat protein (gp120) of HIV
129. Dextran sulfate and other polyanionic anti-HIV compounds specifically interact with the viral gp120 glycoprotein expressed by T-cells persistently infected with HIV-1
130. Sodium pentosan polysulfate (PPS), an anti-HIV agent also exhibits synergism with AZT, lymphoproliferative activity, and virus enhancement
131. Sulfated polysaccharides as potent inhibitors of HIV-induced syncytium formation: A new strategy towards AIDS chemotherapy
132. Effect of pentosan polysulfate (SP 54) on the reverse transcriptase activity of several retroviruses
133. 'Chemical condoms' for the prevention of HIV infection: Evaluation of novel agents against SHIV(89.6PD) in vitro and in vivo
134. Novel sulfonated and phosphonated analogs of distamycin which inhibit the replication of HIV
135. Synthesis and evaluation of oligo-1,3-thiazolecarboxamide derivatives as HIV-1 reverse transcriptase inhibitors
136. Highly potent synthetic polyamides, bisdistamycins, and lexitropsins as inhibitors of human immunodeficiency virus type 1 integrase
137. Small molecule inhibitor of HIV-1 cell fusion blocks chemokine receptor-mediated function
138. Research on anti-HIV-1 agents. Investigation on the CD4-Suradista binding mode through docking experiments
139. The V3 region of the envelope glycoprotein of human immunodeficiency virus type 1 binds sulfated polysaccharides and CD4-derived synthetic peptides
140. Interaction of angiogenic basic fibroblast growth factor with endothelial cell heparan sulfate proteoglycans: Biological implications in neo-vascularization
141. A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: Inhibition of human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry
142. Anti-human immunodeficiency virus type 1 activity of an oligocationic compound mediated via gp120 V3 interactions
143. Inhibition of HIV-1 Tat-TAR interaction by diphenylfuran derivatives: Effects of the terminal basic side chains
144. Aminoglycoside antibiotics, neamine and its derivatives as potent inhibitors for the RNA-protein interactions derived from HIV-1 activators
145. HIV-1 Tat protein promotes formation of more-processive elongation complexes
146. S-adenosylhomocysteine hydrolase inhibitors interfere with the replication of human immunodeficiency virus type 1 through inhibition of the LTR transactivation
147. Carbocyclic adenosine analogues as S-adenosylhomocysteine hydrolase inhibitors and antiviral agents: Recent advances
148. Cooperative inhibition of NF-κ B and Tat-induced superactivation of human immunodeficiency virus type 1 long terminal repeat
149. Dual-target inhibition of HIV-1 in vitro by means of an adeno-associated virus antisense vector
150. + monocytic cells treated with multitargeting HIV-1 antisense sequences incorporated into U1 snRNA
151. Multivalent anti-CCR ribozymes for stem cell-based HIV type 1 gene therapy
152. + T cells from HIV-infected individuals that express intracellular antibodies against HIV-1 gp120 or Tat
153. Inhibition of human immunodeficiency virus type 1 replication in vitro by a novel combination of anti-Tat single-chain intrabodies and NF-κ B antagonists